CAR-T Cell Therapy Targets Tumor Macrophages to Overcome Immunotherapy Resistance in Metastatic Cancer
Key Insights
Scientists at Mount Sinai developed a novel CAR-T cell therapy that targets tumor-protecting macrophages instead of cancer cells directly, converting these immune suppressors into cancer-fighting allies.
The experimental treatment demonstrated striking results in preclinical models of metastatic lung and ovarian cancer (search), with many mice achieving complete cures and surviving months longer than controls.
The therapy works by eliminating tumor macrophages while producing interleukin-12 (search) to activate killer T cells, creating an antigen-independent approach that could potentially treat multiple cancer types.
Scientists at the Icahn School of Medicine at Mount Sinai have developed a groundbreaking immunotherapy approach that targets the cellular guardians protecting tumors rather than attacking cancer cells directly. The experimental treatment, published in Cancer Cell, demonstrated remarkable efficacy in aggressive preclinical models of metastatic ovarian and lung cancer (search), offering new hope for treating advanced-stage solid tumors that have proven resistant to current immunotherapies.
Revolutionary "Trojan Horse" Strategy
The innovative approach models itself after the legendary Trojan horse, infiltrating tumors by targeting macrophages—immune cells that tumors reprogram to serve as protective shields. "What we call a tumor is really cancer cells surrounded by cells that feed and protect them. It's a walled fortress," explained lead study author Jaime Mateus-Tique, PhD. "With immunotherapy, we kept running into the same problem—we can't get past this fortress's guards. So, we thought: what if we targeted these guards, turned them from protectors to friends, and used them as a gateway to bring a wrecking force within the fortress."
In healthy tissues, macrophages function as first responders, fighting infection and facilitating tissue repair. However, within tumors, these cells undergo reprogramming that transforms them into cancer protectors, actively blocking immune attacks and helping malignancies survive and spread. This protective mechanism represents a major barrier to effective cancer immunotherapy.
Engineered CAR-T Cells Target Tumor Macrophages
The research team engineered specialized CAR-T cells (search)—immune cells derived from patients' own T cells—to specifically recognize and eliminate tumor macrophages while sparing normal ones. Unlike conventional CAR-T therapies designed to target cancer cells directly, this approach focuses on dismantling the tumor's protective infrastructure.
The engineered CAR-T cells (search) carry an additional modification: they produce interleukin-12 (search), a potent immune-activating molecule specialized in activating killer T cells. This dual mechanism allows the therapy to both eliminate immune-suppressing macrophages and simultaneously recruit cancer-fighting immune cells to the tumor site.
Striking Preclinical Results
When researchers treated mice with metastatic lung and ovarian cancers using their engineered CAR-T cells (search), the results proved remarkable. Treated mice survived for months longer than controls, with many achieving complete cures. The therapy's effectiveness across two different cancer types highlights its potential as a broad-spectrum treatment approach.
Advanced spatial genomics techniques revealed the therapy's mechanism of action within tumors. The treatment successfully reshaped the tumor microenvironment, removing immune-suppressing cells and drawing in immune cells capable of killing cancer. This transformation converts tumors from immune-suppressed environments into immune-active battlegrounds where the body's natural defenses can effectively combat malignancy.
Antigen-Independent Therapeutic Approach
The therapy represents a significant advancement because it operates independently of specific tumor antigens, potentially enabling treatment of diverse cancer types not traditionally amenable to immunotherapy. "Macrophages are found in every type of tumor, sometimes outnumbering the cancer cells. They're there because the tumor uses them as a shield," noted senior author Brian Brown, PhD, Director of the Icahn Genomics Institute. "What's so exciting is that our treatment converts these cells from protecting the cancer to killing it. We've turned foe into ally."
This antigen-independent characteristic addresses a major limitation of current CAR-T therapies, which often struggle to identify suitable targets on cancer cells. By focusing on the tumor's support infrastructure rather than cancer cells themselves, the approach could potentially treat cancers that have proven refractory to existing immunotherapies.
Path to Clinical Translation
The research team emphasizes that human studies remain necessary to determine safety and efficacy in patients, cautioning that results should be viewed as proof of concept rather than a cure. Current efforts focus on refining the approach, particularly by improving control over interleukin-12 (search) release within tumors to maximize effectiveness while ensuring safety for potential human testing.
"This establishes a new way to treat cancer," stated Dr. Brown. "By targeting tumor macrophages, we've shown that it can be possible to eliminate cancers that are refractory to other immunotherapies." The strategy could serve as a foundation for future CAR-T therapies that reshape tumors by targeting support cells rather than cancer cells alone, potentially expanding treatment options for patients with metastatic disease.